Business Description
Lumosa Therapeutics Co Ltd
ISIN : TW0006535008
Total Employee Number:
30Description
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 115.33 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 76.72 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.6 | |||||
3-Year EBITDA Growth Rate | 12 | |||||
3-Year EPS without NRI Growth Rate | 12.3 | |||||
3-Year FCF Growth Rate | -5.3 | |||||
3-Year Book Growth Rate | -3.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.56 | |||||
9-Day RSI | 42.33 | |||||
14-Day RSI | 39.65 | |||||
3-1 Month Momentum % | -22.3 | |||||
6-1 Month Momentum % | -42.55 | |||||
12-1 Month Momentum % | -24.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.37 | |||||
Quick Ratio | 6.62 | |||||
Cash Ratio | 6.09 | |||||
Days Inventory | 2536.98 | |||||
Days Sales Outstanding | 103.66 | |||||
Days Payable | 23.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 0.34 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.05 | |||||
Operating Margin % | -930.77 | |||||
Net Margin % | -950.41 | |||||
EBITDA Margin % | -935.39 | |||||
FCF Margin % | -1006.1 | |||||
OCF Margin % | -1006.1 | |||||
ROE % | -20.17 | |||||
ROA % | -18.26 | |||||
ROIC % | -43.06 | |||||
3-Year ROIIC % | -19.03 | |||||
ROC (Joel Greenblatt) % | -713.67 | |||||
ROCE % | -20.33 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 29.72 | |||||
PS Ratio | 465.28 | |||||
PB Ratio | 11.22 | |||||
Price-to-Tangible-Book | 11.22 | |||||
EV-to-EBIT | -46.33 | |||||
EV-to-EBITDA | -47.89 | |||||
EV-to-Revenue | 447.95 | |||||
EV-to-FCF | -44.52 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Median-PS-Value | 1.95 | |||||
| Price-to-Net-Current-Asset-Value | 20.51 | |||||
| Price-to-Net-Cash | 25.77 | |||||
Earnings Yield (Greenblatt) % | -2.16 | |||||
FCF Yield % | -2.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lumosa Therapeutics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 35.831 | ||
| EPS (TTM) (NT$) | -2.06 | ||
| Beta | 0.6736 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 91.11 | ||
| 14-Day RSI | 39.65 | ||
| 14-Day ATR (NT$) | 4.487629 | ||
| 20-Day SMA (NT$) | 101.97 | ||
| 12-1 Month Momentum % | -24.74 | ||
| 52-Week Range (NT$) | 96.9 - 329.5 | ||
| Shares Outstanding (Mil) | 167.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lumosa Therapeutics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lumosa Therapeutics Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lumosa Therapeutics Co Ltd Frequently Asked Questions
What is Lumosa Therapeutics Co Ltd(ROCO:6535)'s stock price today?
The current price of ROCO:6535 is NT$100.50. The 52 week high of ROCO:6535 is NT$329.50 and 52 week low is NT$96.90.
When is next earnings date of Lumosa Therapeutics Co Ltd(ROCO:6535)?
The next earnings date of Lumosa Therapeutics Co Ltd(ROCO:6535) is .
Does Lumosa Therapeutics Co Ltd(ROCO:6535) pay dividends? If so, how much?
Lumosa Therapeutics Co Ltd(ROCO:6535) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Lumosa Therapeutics Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers